Caroline R. Stanton

This study identifies potent PDIA1 inhibitors that block NLRP3 inflammasome activity without significant cellular toxicity, offering a strategy to treat diseases involving hyperactive NLRP3.

This study shows that inhibiting PGK1 with CBR-470-2 reduces NF-κB signaling by increasing methylglyoxal, which inactivates NF-κB proteins.

This study shows methylglyoxal, a glycolytic metabolite, covalently inactivates the NLRP3 inflammasome by forming crosslinks, thereby reducing inflammation.

This study shows that AA147 inhibits NLRP3 inflammasome activity by covalently modifying PDIA1, suggesting PDIA1 as a therapeutic target for inflammatory diseases.